Trial Profile
An Open, Randomized, Multicenter Study in Patients With Recurrent Epithelian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer to Compare the Efficay and Safety of Paclitaxel (Micellar) Nanoparticles and Paclitaxel (Cremophor EL)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Carboplatin
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Squamous cell cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Oasmia Pharmaceutical; Vivesto
- 09 Dec 2019 Results published in the Gynecologic Oncology
- 25 Mar 2019 Results of subgroup analysis presented in the Oasmia Pharmaceutical Media Release.
- 25 Mar 2019 According to an Oasmia Pharmaceutical media release, the results of the subpopulation analysis of the patients corresponding to the approved indication, i.e patients experiencing their first relapse, were based on 301 patients (Apealea arm) and 298 patients (Comparator arm).